ABNOM
☆ AI Dermatology — Free Service
2022. gada Stiftung Warentest rezultātos no Vācijas patērētāju apmierinātība ar ModelDerm bija tikai nedaudz zemāka nekā ar maksas telemedicīnas konsultācijām.
2022. gada Stiftung Warentest rezultātos no Vācijas patērētāju apmierinātība ar ModelDerm bija tikai nedaudz zemāka nekā ar maksas telemedicīnas konsultācijām.
relevance score : -100.0%
ReferencesIr zināms, ka Q‑switched Nd:YAG lāzers efektīvi ārstē Ota nevus un līdzīgus apstākļus. Mēs veicām pētījumu, lai noskaidrotu, cik labi high‑fluence 1064 nm Q‑switched Nd:YAG lāzers iedarbojas uz mongoļu plankumiem neparastās vietās, neradot ādas gaišumu. Mēs pētījām 61 pacientu ar šiem plankumiem, kopumā pārbaudot 70 bojājumus. Puse no bojājumiem tika ārstēta ar lāzeru, bet pārējie tika atstāti neārstēti salīdzinājumam. Rezultātus novērtējām, izmantojot skalas novērtējumu un ierīci, ko sauc par Mexameter®, melanīna līmeņa mērīšanai. Pacienti tika novēroti vidēji 14 mēnešus ārstēšanas grupā un 18 mēnešus novērošanas grupā. Pētījuma beigās mēs atklājām būtiskas atšķirības skalas rādītājos un melanīna līmeņos starp ārstētajām un neapstrādātajām grupām; lāzeru apstrādātā grupa uzrādīja labākus rezultātus. High‑fluence Q‑switched Nd:YAG lāzers, neradot ādas apgaismojumu, izrādījās efektīvs un drošs šādu neparastu mongoļu plankumu ārstēšanā.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Mēs pētījām konkrētas lāzerterapijas lietošanas efektivitāti un drošību ABNOM, un noskaidrojām, kādi faktori varētu ietekmēt tās darbību. Mēs analizējām 110 pacientus, kuriem bija ABNOM, un kuriem tika veiktas divas līdz deviņas lāzerterapijas sesijas. Atklājām, ka ārstēšana bija efektīvāka, ja tā tika veikta ilgāk, bet mazāk efektīva gados vecākiem pacientiem. Tā arī sniedza labākus rezultātus pacientiem ar gaišāku ādu (III tips) un mazākām skartajām zonām (mazāk nekā 10 cm²). Melasma kopā ar ABNOM samazināja ārstēšanas efektivitāti. Skarto zonu krāsa vai skaits neizrādījās būtisks faktors. Aptuveni 10 % pacientu pēc ārstēšanas izrādīja tumšākus plankumus. Agrīna vairākkārtēja ārstēšana deva labus rezultātus. Gados vecākiem pacientiem ar tumšāku ādu un tumšākiem plankumiem pēc ārstēšanas ir lielāka iespēja izveidot tumšākus plankumus. Pacientiem ar ABNOM un melasmu ir ieteicams izmantot zemāku lāzera enerģiju, lai nepasliktinātu melasmu.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Ārstēšana
Balināšanas līdzekļi reti palīdz. Atšķirībā no melasmas, ABNOM var uzlabot ar lāzera ārstēšanu, un rezultāts var saglabāties bez recidīva. Ārstēšanu ar lāzeru parasti veic 10–20 reizes.
#QS1064 laser